scispace - formally typeset
Search or ask a question
BookDOI

Health Care and Cost Containment in the European Union

TL;DR: Part 1: health care and cost containment in the EU - an overview - health care systems, health care spending, cost containment measures,cost containment measures in practice, Eli Mossialos and Julian Le Grand and Panos Kanovos.
Abstract: Part 1: health care and cost containment in the EU - an overview - health care systems, health care spending, cost containment measures, cost containment measures in practice, Eli Mossialos and Julian Le Grand cost containment and health expenditure in the EU - a macroeconomic perspective, Panos Kanovos is there convergence in health expenditures of the EU member states?, Adelina Comas-Herrera. Part 2: cost containment and health care reform in Belgium, David Crainich and Marie-Christine Closon health care and cost containment in Denmark, Terkel Christiansen et al cost containment in Germany - 20 years experience, Reinhard Busse and Chris Howorth cost containment and health care in Greece, Aris Sissouras et al cost containment in health care - the case of Spain, Guillem Lopez i Casanovas 20 years of cures for the French health care system, Pierre-Jean Lancry and Simone Sandier health expenditure and cost containment in Ireland, Jenny Hughes cost containment and structural reforms in the Italian national health service, Giovanni Fattore cost containment in health care - the case of Luxembourg, Elias Mossialos developments in health care cost containment in the Netherlands, Mirjam van het Loo et al health expenditure and cost control in Austria, Engerbert Theurl health care reform and cost containment in Portugal, Joao Pereira et al cost containment in Finnish health care, Unto Hakkinen health care forms and cost containment - the Swedish experience, Anders Anell and Patrick Svarvar cost containment and health care reforms in the British NHS, Giovanni Fattore.
Citations
More filters
Book
01 Apr 2002
TL;DR: This book discusses financing health care taxation and the alternatives in central and eastern Europe and the former Soviet Union, as well as issues, trends and policy implications.
Abstract: Notes on contributors Series editors' preface Foreword Funding health care an introduction Financing health care taxation and the alternatives Social health insurance financing Health financing reforms in central and eastern Europe and the former Soviet Union Private health insurance and medical savings accounts theory and experience Voluntary health insurance in the European Union User charges for health care Informal health payments in central and eastern Europe and the former Soviet Union issues, trends and policy implications Lessons on the sustainability of health care funding from low- and middle- income countries Funding long-term care the public and private options Strategic resource allocation and funding decisions Funding health care in Europe weighing up the options References Index.

332 citations

Report SeriesDOI
TL;DR: Evidence on the effects of PHI in different national contexts is assessed and conclusions about its role in health financing and roles are drawn.
Abstract: Governments often look to private health insurance (PHI) as a possible means of addressing some health system challenges. For example, they may consider enhancing its role as an alternative source of health financing and a way to increase system capacity, or promoting it as a tool to further additional health policy goals, such as enhanced individual responsibility. In some countries policy makers regard PHI as a key element of their health coverage systemsWhile private health insurance represents, on average, only a small share of total health funding across the OECD area, it plays a significant role in health financing in some OECD countries and it covers at least 30% of the population in a third of the OECD members. It also plays a variety of roles, ranging from primary coverage for particular population groups to a supporting role for public systems.This paper assesses evidence on the effects of PHI in different national contexts and draws conclusions about its ...

290 citations

Journal ArticleDOI
TL;DR: U.S. citizens spent $5,267 per capita for health care in 2002--53 percent more than any other country; two possible reasons for the differential are supply constraints that create waiting lists in other countries and the level of malpractice litigation and defensive medicine in the United States.
Abstract: U.S. citizens spent $5,267 per capita for health care in 2002—53 percent more than any other country. Two possible reasons for the differential are supply constraints that create waiting lists in other countries and the level of malpractice litigation and defensive medicine in the United States. Services that typically have queues in other countries account for only 3 percent of U.S. health spending. The cost of defending U.S. malpractice claims is estimated at $6.5 billion in 2001, only 0.46 percent of total health spending. The two most important reasons for higher U.S. spending appear to be higher incomes and higher medical care prices.

246 citations

Journal Article
TL;DR: In this article, the authors present a list of policy options for decision-makers in Central and Eastern European economies in transition, including generic drug marketing regulation, reference pricing, pricing of branded originator products, and the degree of price competition in pharmaceutical markets.
Abstract: Generic drugs have a key role to play in the efficient allocation of financial resources for pharmaceutical medicines. Policies implemented in the countries with a high rate of generic drug use, such as Canada, Denmark, Germany, the Netherlands, the United Kingdom, and the United States, are reviewed, with consideration of the market structures that facilitate strong competition. Savings in these countries are realized through increases in the volume of generic drugs used and the frequently significant differences in the price between generic medicines and branded originator medicines. Their policy tools include the mix of supply-side measures and demand-side measures that are relevant for generic promotion and higher generic use. On the supply-side, key policy measures include generic drug marketing regulation that facilitates market entry soon after patent expiration, reference pricing, the pricing of branded originator products, and the degree of price competition in pharmaceutical markets. On the demand-side, measures typically encompass influencing prescribing and dispensing patterns as well as introducing a co-payment structure for consumers/patients that takes into consideration the difference in cost between branded and generic medicines. Quality of generic medicines is a pre-condition for all other measures discussed to take effect. The paper concludes by offering a list of policy options for decision-makers in Central and Eastern European economies in transition.

200 citations

Journal ArticleDOI
TL;DR: A typology to classify provider payment systems from an incentive point of view is developed and provides a useful framework for future research of health care payment systems.

177 citations


Cites background from "Health Care and Cost Containment in..."

  • ...Indeed, in many countries budgets are frequently exceeded [9]....

    [...]